Tag Archives: slxp

Salix Pharma Stock Falls Despite Tax-Inversion Deal

Specialty drugmaker and IBD 50 stock Salix Pharmaceuticals (SLXP) was down more than 4% in morning trading on the stock market today despite announcing a tax-inversion merger late Tuesday, as analysts were underwhelmed by the near-term benefits of the deal. In a stock swap, Salix agreed to merge with Cosmo Technologies, the Irish subsidiary of Italian drugmaker Cosmo Pharmaceuticals, which like Salix focuses on gastrointestinal diseases. Raleigh,

Salix, Akorn, Regeneron Lead Drug Stock Rally

Biotech and pharma stocks rallied Tuesday as several leading players reported good news amid a buoyant market day. IBD 50 specialty drugmaker Salix Pharmaceuticals (SLXP) shot up to a new high of 143.98 before closing up 13.5% at 140.02. Salix said Tuesday that sufferers from irritable bowel syndrome with diarrhea showed statistically significant improvement in symptoms when they took its drug Xifaxan in a phase-three clinical trial.

Salix Pharma’s Lead Drug Scores Against Bowel Disease

Specialty drugmaker and IBD 50 stock Salix Pharmaceuticals (SLXP) said Tuesday that its drug Xifaxan succeeded in a late-stage study of irritable bowel syndrome with diarrhea, sending Salix stock up more than 11% to a new high in morning trading on the stock market today. The Salix press release provided few numbers but said that patients in the phase-three study who took Xifaxan, known generally as rifaximin, for 14 days showed statistically